ANGLE’s Parsortix system has the potential to deliver profound improvements in clinical and health economic outcomes in the treatment and diagnosis of various forms of cancer.”
Andrew Newland
Chief Executive

The Parsortix system is simple, effective and affordable

  • The system captures cells that aren’t being caught by antibody-based systems
    • Antibody based systems can miss key cells such as mesenchymal cells and will not work well for some cancers such as ovarian cancer
  • Easy access to the CTCs to feed a wide range of downstream analysis
    • Alternative size-based enrichment systems (such as membrane systems) can find it difficult to recover the captured cells to allow for further analysis.
  • Plasma for ctDNA analysis can be removed prior to processing the cellular component of a blood sample – hence ctDNA and CTCs from a single sample.
  • Cells recovered from the Parsortix system are viable
  • Simple operation with minimal user intervention required.
Breaking news: Research with Parsortix in prostate cancer View Here